Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

enVVeno Medical (NVNO) Depreciation & Amortization (CF) (2017 - 2020)

enVVeno Medical has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $26297.0 for Q4 2020.

  • For Q4 2020, Depreciation & Amortization (CF) fell 31.87% year-over-year to $26297.0; the TTM value through Dec 2020 reached $97549.0, down 21.12%, while the annual FY2025 figure was $136000.0, 28.04% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2020 was $26297.0 at enVVeno Medical, roughly flat from $26291.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $38600.0 in Q4 2019 and troughed at $19676.0 in Q1 2020.
  • A 4-year average of $30066.4 and a median of $33126.5 in 2017 define the central range for Depreciation & Amortization (CF).
  • On a YoY basis, Depreciation & Amortization (CF) climbed as much as 14.78% in 2019 and fell as far as 32.32% in 2019.
  • Year by year, Depreciation & Amortization (CF) stood at $33254.0 in 2017, then increased by 1.13% to $33629.0 in 2018, then grew by 14.78% to $38600.0 in 2019, then plummeted by 31.87% to $26297.0 in 2020.
  • Business Quant data shows Depreciation & Amortization (CF) for NVNO at $26297.0 in Q4 2020, $26291.0 in Q3 2020, and $25285.0 in Q2 2020.